Sangui Bio Tech International Inc.

EANS-News: CE mark granted for wound spray based on Sangui patent

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Patents, Copyright & Trademarks/Sales start

Subtitle: Sales start under Granulox brand name imminent

Witten (euro adhoc) - Based on a patent by Sangui, the technology for a spray
aiming at improved healing of chronic wounds is now available. According to a
notification by SastoMed GmbH a certification as class III medical product was
granted. Global licensee SastoMed will be in charge of marketing and
distribution. The CE mark according to sections 6 and 7 of the Medical Devices
Act authorizes production, distribution and sales of the product in all member
countries of the European Union. SastoMed have also informed SanguiBioTech GmbH
that the market entry of the product is imminent.
SastoMed Managing Director Michael Sander said: "This is a definitive
breakthrough enabling us to capitalize on the great opportunities this unique
product offers. We now sell the only therapeutic which can help to soothe the
problem of hypoxia i.e. the lack of oxygen supply to chronic wounds. This
technology can be regarded as a significant innovation in wound treatment.
Already, we experience numerous individual requests and a growing awareness
among leading wound management experts. We are excited to offer them a highly
effective supplement to the existing treatments."
The CE mark certification for Granulox was obtained only 16 months after the
founding of the joint venture company SastoMed by SanguiBioTech GmbH and
SanderStrothman GmbH and well ahead of the initial two year road map. Numerous
additional inquiries were required to prepare the demanding documentation for
the certification as class III medical product, cornerstone of the process of
converting the patent into a production process, impeccable both from an
economic and authorization point of view. In addition, preparatory works
included the developing of completely new manufacturing processes yielding
considerable efficiency improvements.
"With the imminent market entry of the product our company enters a new stage",
Hubertus Schmelz, Managing Director of SanguiBioTech GmbH emphasized. "It also
confirms that the cooperation with SanderStrothmann was and continues to be a
decisive step ahead for us with both sides now benefiting from the
professionalism and the good mutual relationship established over the past
years."
Details of the sales plan as well as of future activities are to be disclosed in
due course.


Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (160) 741 27 17
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     Sangui Bio Tech International Inc.
             Alfred-Herrhausen-Strasse 44
             D-58455 Witten
phone:       +49(0)2302 915-200
FAX:         +49(0)2302 915-191
mail:     info@sangui.de
WWW:      http://www.sanguibiotech.com
sector:      Biotechnology
ISIN:        DE0000906757
indexes:     
stockmarkets: free trade: Hamburg, New York 
language:   English
 



Weitere Meldungen: Sangui Bio Tech International Inc.

Das könnte Sie auch interessieren: